Please login to the form below

Not currently logged in
Email:
Password:

Kala Pharma appoints Fovea founder Bernard Gilly to board

He previously formed the company that became Sanofi’s ophthalmology business

Dr Bernard Gilly, founder and CEO of Sanofi-owned Fovea, has joined the board of Kala Pharmaceuticals.

He brings years of experience in eye treatment to Kala, which is developing mucosal penetrating products in a number of ophthalmic diseases.

“Dr Gilly is a seasoned entrepreneur in the biotechnology industry having spent over 20 years building and investing in leading life science companies,” said Dr Guillaume Pfefer, Kala's president and CEO.

“His track record and expertise in the ophthalmology space is an invaluable addition to Kala as we advance our pipeline of transformative ophthalmic products into the clinic.”

Dr Gilly, along with Professor Jose Sahel and Pierre Belichard, set up Fovea in 2005. The company was acquired by Sanofi in 2009, becoming the French pharma firm's ophthalmology division.

Prior to his involvement with Fovea, Dr Gilly was a venture partner with Sofinnova Partners from 2000 to 2005.

He also served as a co-president and VP of R&D of Sanofi Pasteur and VP of R&D of BioMérieux.

His other entrepreneurial efforts include helping to found several biotech companies, including Domain Therapeutics, WebSurg, Kutexis, GenSight Biologicals, Pixium Vision and Enterome. He currently serves as chair at the latter three companies.

29th November 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...